Celltrion Submits An ABLA For Actemra® (Tocilizumab) Pr

On January 28, 2024 Celltrion announced the submission to the FDA of an aBLA for CT-P47, a proposed biosimilar of Genentech's Actemra® (tocilizumab).

Related Keywords

United States , India , Quinn Emanuel Urquhart Sullivan , Livingston Mattesich , Los Angeles , Cowan Liebowitz Latman , Foley Lardner , Obhan Associates , Supreme Court , Intellectual Property , Comparative Guide , Mondaq , Celltrion Submits An Abla For Actemra Xae Tocilizumab Proposed Biosimilar Ct P47 , Patent , ,